Current perspectives of catabolic mediators of cancer cachexia

Medical Science Monitor

Volumn 13, Issue 9, 2007, Pages

  Lelbach, Adam ^a   Muzes, Gyorgyi ^a   Feher, Janos ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cancer cachexia; Cytokines; Mediators; Metabolic changes

Indexed keywords

ACUTE PHASE PROTEIN; CARBOHYDRATE; CILIARY NEUROTROPHIC FACTOR; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; GLUCOSE; IBUPROFEN; ICOSAPENTAENOIC ACID; INDOMETACIN; INSULIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN; LIPID; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NEUROTRANSMITTER; PENTOXIFYLLINE; PREDNISOLONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNINDEXED DRUG;

ACUTE PHASE RESPONSE; ANEMIA; ANOREXIA; ASTHENIA; CACHEXIA; CANCER CACHEXIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARBOHYDRATE METABOLISM; CATABOLISM; CORRELATION ANALYSIS; DEPRESSION; ENERGY EXPENDITURE; FOOD INTAKE; GASTROINTESTINAL OBSTRUCTION; GLUCOSE INTOLERANCE; HUMAN; HUMORAL IMMUNITY; HYPERMETABOLISM; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISORDER; NEUROTRANSMISSION; NONHUMAN; NUTRIENT; PAIN; PROGNOSIS; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; SURVIVAL TIME; WEIGHT REDUCTION;

ACUTE DISEASE; ANIMALS; ANOREXIA; BIOLOGICAL MARKERS; CACHEXIA; HUMANS; NEOPLASMS;

EID: 34548674236     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Monitto CL, Berkowitz D, Lee KM et al: Differential gene expression in a murine model of cancer cachexia. Am J Physiol Endocrinol Metab, 2001; 281: 289-97
2. Gibney E, Elia M, Jebb SA et al: Total energy expenditure in patients with small-cell lung cancer: results of a validated study using the bicarbonate-urea method. Metabolism, 1997; 46: 1412-17
3. Dworzak F, Ferrari P, Gavazzi C et al: Effects of cachexia due to cancer on whole body and skeletal muscle protein turnover. Cancer, 1998; 82: 42-48
4. Giordano A, Calvani M, Petillo O et al: Skeletal muscle metabolism in physiology and in cancer disease. J Cell Biochem, 2003; 90: 170-86
5. Fearon KC, Falconer JS, Slater C et al: Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg, 1998; 227: 249-54
6. Preston T, Slater C, McMillan DC et al: Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. J Nutr, 1998; 128: 1355-60
7. Harvie MN, Campbell IT, Thatcher N et al: Changes in body composition in men and women with advanced nonsmall cell lung cancer (NSCLC) undergoing chemotherapy. J Hum Nutr Diet, 2003; 16: 323-26
8. Nielsen HJ, Pappot H, Christensen IJ et al: Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ, 1998; 316: 829-30
9. Vidal-Vanaclocha F, Amézaga C, Asumendi A et al: Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res, 1994; 54: 2667-72
10. Argiles JM, Moore-Carrasco R, Busquets S et al: Catabolic mediators as targets for cancer cachexia. Drug Discov Today, 2003; 8: 838-44
11. Argiles JM, Moore-Carrasco R, Fuster G et al: Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol, 2003, 35, 405-9
12. Lelbach A, Muzes Gy, Fehér J: Molecular mechanisms of cancer cachexia. Orv Hetil, 2004; 46: 2329-34
13. Brink M, Anwar A, Delafontaine P: Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int J Cardiol, 2002; 85: 111-21
14. Inui A: Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res, 1999; 59: 4493-501
15. Inui A, Meguid MM: Cachexia and obesity: two sides of one coin? Curr Opin Clin Nutr Metab Care, 2003; 6: 395-99
16. Bessey PQ, Watters JM, Aoki TT et al: Combined hormonal infusion stimulates the metabolic response to injury. Ann Surg, 1984; 200: 264-81
17. Watters JM, Bessey PQ, Dinarello CA et al: Both inflammatory and endocrine mediators stimulate host responses to sepsis. Arch Surg, 1986; 121: 179-90
18. Geisterfer M, Richards C, Baumann M et al: Regulation of IL-6 and the hepatic IL-6 receptor in acute inflammation in vivo. Cytokine, 1993; 5: 1-7
19. Schaur RJ, Fellier H, Gleispach H et al: Tumor host relations. I. Increased plasma cortisol in tumor-bearing humans compared with patients with benign surgical diseases. J Cancer Res Clin Oncol, 1979; 93: 281-85
20. Knapp ML, al-Sheibani S, Riches PG et al: Hormonal factors associated with weight loss in patients with advanced breast cancer. Ann Clin Biochem, 1991; 28: 480-86
21. Besedovsky HO, del Rey A, Schardt M et al: Changes in plasma hormone profiles after tumor transplantation into syngenetic and allogenetic rats. Int J Cancer, 1985; 36: 209-16
22. Baumann H, Gauldie J: The acute phase response. Immunol Today, 1994; 15: 74-80
23. Holroyde CP, Skutches CL, Boden G et al: Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res, 1984; 44: 5910-13
24. Ding X, Flatt PR, Permert J et al: Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology, 1998; 114: 130-38
25. Simons JP, Schols AM, Campfield LA et al: Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci, 1997; 93: 273-77
26. Aleman MR, Santolaria F, Batista N et al: Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine, 2002; 19: 21-26
27. Crown AL, Cottle K, Lightman SL et al: What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol, 2002; 56: 723-33
28. Lazarus DD, Kambayashi T, Lowry S et al: The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-2-mediated cancer cachexia. Cancer Lett, 1996; 103: 71-77
29. Anker SD, Volterrani M, Pflaum CD et al: Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol, 2001; 38: 443-52
30. Lelbach A, Scharf JG, Ramadori G: Regulation of insulin-like growth factor-I and of insulin-like growth factor binding protein-1, -3 and -4 in cocultures of rat hepatocytes and Kupffer cells by interleukin-6. J Hepatol, 2001; 35: 558-67
31. Lieberman SA, Butterfield GE, Harrison D et al: Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab, 1994; 78: 404-10
32. von Laue S, Ross RJ: Inflammatory cytokines and acquired growth hormone resistance. Growth Horm IGF Res, 2000; 10: 9-14
33. Simons JP, Schols AM, Buurman WA et al: Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci, 1999; 97: 215-23
34. Lelbach A, Muzes Gy, Feher J: The insulin-like growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases. Acta Physiol Hung, 2005; 92: (in press)
35. Maile LA, Holly JMP: Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation. Growth Horm IGF Res, 1999; 9: 85-95
36. Argiles JM, Busquets S, Lopez-Soriano FJ: Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care, 2003; 6: 401-6
37. Chung YC, Chang YF: Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol, 2003; 15: 369-73
38. Trikha M, Corringham R, Klein B et al: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res, 2003; 15: 4653-65
39. Smith BK, Kluger MJ: Anti-TNF-α antibodies normalised body temperature and enhanced food intake in tumor-bearing rats. Am J Physiol, 1993; 265: 615-19
40. Emilie D, Wijdenes J, Gissebrecht C et al: Administration of anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood, 1994; 84: 2472-79
41. Shibata M, Nezu T, Kanou H et al: Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol, 2002; 34: 416-20
42. Ladner KJ, Caligiuri MA, Guttridge DC: Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem, 2003; 278: 2294-303
43. Penner CG, Gang G, Wray C et al: The transcription factors NF-kappab and AP-1 are differentially regulated in skeletal muscle during sepsis. Biochem Biophys Res Commun, 2001; 281: 1331-36
44. Tisdale MJ: Biomedicine. Protein loss in cancer cachexia. Science, 2000; 289: 2293-94
45. Cariuk P, Lorite MJ, Todorov PT et al: Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer, 1997; 76: 606-13
46. Hirai K, Ishiko O, Tisdale M: Mechanism of depletion of liver glycogen in cancer cachexia. Biochem Biophys Res Commun, 1997; 241: 49-52
47. Fujiki F, Mukaida N, Hirose K et al: Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res, 1997; 57: 94-99
48. Barber MD, Fearon KC, Delmore G et al: Should cancer patients with incurable disease receive parenteral or enteral nutritional support? Eur J Cancer, 1998; 34: 279-85
49. McCarthy DO: Rethinking nutritional support for persons with cancer cachexia. Biol Res Nurs, 2003; 5: 3-17
50. von Haehling S, Genth-Zotz S, Anker SD et al: Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol, 2002; 85: 173-83
51. Davis TW, Zweifel BS, O'Neal JM et al: Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther, 2004; 308: 929-34
52. Psaty BM, Furberg CD: COX-2 Inhibitors - Lessons in Drug Safety. N Engl J Med, 2005; (10.1056/NEJMe058042)
53. Ghezzi P, Cerami A: Tumor necrosis factor as a pharmacological target. Methods Mol Med, 2004; 98: 1-8
54. Jho D, Babcock TA, Helton WS et al: Omega-3 fatty acids: implications for the treatment of tumor-associated inflammation. Am Surg, 2003; 69: 32-36
55. Wigmore SJ, Fearon KC, Ross JA: Modulation of human hepatocyte acute phase protein production in vitro by n-3 and n-6 polyunsaturated fatty acids. Ann Surg, 1997; 225: 103-11
56. Barber MD, Ross JA, Preston T et al: Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. J Nutr, 1999; 129: 1120-25
57. Barber MD, Ross JA, Voss AC et al: The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer, 1999; 81: 80-86
58. Wigmore SJ, Barber MD, Ross JA et al: Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer, 2000; 36: 177-84
59. McMillan DC, O'Gorman P, Fearon KC et al: A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer, 1997; 76: 788-90
60. McMillan DC, Wigmore SJ, Fearon KC et al: A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer, 1999; 79: 495-500
61. Fearon KC, Moses AG: Cancer cachexia. Int J Cardiol, 2002; 85: 73-81
62. Rubin H: Systemic effects of cancer: role of multiple proteases and their toxic peptide products. Med Sci Monit, 2005, 11(7), RA221-28
63. Konturek PC, Kania J, Konturek JW et al: H. pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPAR gamma and impaired apoptosis in gastric carcinogenesis. Med Sci Monit, 2003; 9(7): SR53-66
64. Mazzoccoli G, Carughi S, De Cata A et al: Melatonin and cortisol serum levels in lung cancer patients at different stages of disease. Med Sci Monit, 2005; 11(6): CR284-88